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SUMMARY: We developed and validated a specific 12-item questionnaire to
evaluate adherence to oral antiresorptive medication by post-menopausal
osteoporotic women in everyday practice. Over the following 9 months, an index
of ≤16 was associated with an increase in the risk of treatment discontinuation of
1.69 and of 2.10 for new patients who had started treatment within the previous
year.
INTRODUCTION: Adherence to medication in osteoporosis is poor. The goal of
this study was to develop and validate a disease-specific questionnaire to evaluate
adherence to treatment of women with post-menopausal osteoporosis taking oral
antiresorptive medication.
METHODS: A prototype adherence questionnaire with 45 items developed from
patient interview, literature review, and physician opinion was evaluated in a
sample of 350 post-menopausal women with osteoporosis treated in primary care.
Item responses were matched against scores on the Morisky Medication
Adherence Scale (MMAS). The most discriminant items were retained in the final
questionnaire. Concurrent and predictive validity were assessed.
RESULTS: Twelve items were associated with MMAS score at a probability level
of 0.05. These were retained in the final questionnaire which provided an
adherence index ranging from 0 to 22. An index of ≥20 was associated with a high
probability of persistence and an index ≤ 16 with a high probability of treatment
discontinuation in the following 9 months.
CONCLUSIONS: The ADEOS-12 is a simple patient-reported measure to
determine adherence to osteoporosis treatments with good concurrent and
discriminant validity. This is the first disease-specific adherence measure to have
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